Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
Holding CRSP?
Track your performance easily
CRSP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$38.20 - $91.10
Previous Close$41.02
Volume1.45M
Average Volume (3M)1.65M
Market Cap
$3.50B
Enterprise Value$1.79B
Total Cash (Recent Filing)$1.94B
Total Debt (Recent Filing)$227.54M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Feb 18, 2025EPS Estimate
-$1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding85,353,479
10 Day Avg. Volume1,643,583
30 Day Avg. Volume1,645,928
Standard Deviation0.19
R-Squared0.21
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.80
Price to Sales (P/S)17.37
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.84
Enterprise Value/Gross Profit7.48
Enterprise Value/Ebitda-9.43
Forecast
1Y Price Target
$67.94Price Target Upside65.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Crispr Therapeutics AG News
Bulls Say, Bears Say
Bulls Say
Financial PositionCRISPR Therapeutics maintains a strong cash position, which is advantageous in conditions of market uncertainty.
Innovative TherapiesThe early response rates are encouraging and suggest CTX112 could potentially have a competitive efficacy profile with a more tolerable safety profile compared to available autologous CD19 CAR-T therapies.
Regulatory ApprovalCRSP announced regulatory approval for Casgevy to treat sickle cell disease and transfusion-dependent thalassemia patients aged 12 and older in Switzerland and Canada.
Bears Say
Market SentimentCurrent investor sentiment towards gene editing is luke-warm, and near-term updates are not seen as key value inflection points.
Product PerformanceResponse rates for CTX112 in large B-cell lymphoma are below those reported for autologous CAR-T therapies like Yescarta and Breyanzi and other treatments in development.
Revenue And Financial PerformanceRevenue expectations for Crispr Therapeutics' product Casgevy might need to be adjusted downward due to slower than expected infusion rates.
---
Ownership Overview
1.66% Insiders
16.53% Mutual Funds
42.69% Other Institutional Investors
22.53% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRSP FAQ
What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest stock price was $38.20 and its highest was $91.10 in the past 12 months.
What is Crispr Therapeutics AG’s market cap?
Currently, no data Available
When is Crispr Therapeutics AG’s upcoming earnings report date?
Crispr Therapeutics AG’s upcoming earnings report date is Feb 18, 2025 which is in 44 days.
How were Crispr Therapeutics AG’s earnings last quarter?
Crispr Therapeutics AG released its earnings results on Nov 05, 2024. The company reported -$1.01 earnings per share for the quarter, beating the consensus estimate of -$1.385 by $0.375.
Is Crispr Therapeutics AG overvalued?
According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.
Does Crispr Therapeutics AG pay dividends?
Crispr Therapeutics AG does not currently pay dividends.
What is Crispr Therapeutics AG’s EPS estimate?
Crispr Therapeutics AG’s EPS estimate is -$1.22.
How many shares outstanding does Crispr Therapeutics AG have?
Crispr Therapeutics AG has 85,353,480 shares outstanding.
What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
Crispr Therapeutics AG reported an EPS of -$1.01 in its last earnings report, beating expectations of -$1.385. Following the earnings report the stock price went down -0.455%.
Which hedge fund is a major shareholder of Crispr Therapeutics AG?
Among the largest hedge funds holding Crispr Therapeutics AG’s share is ARK Investment Management LLC. It holds Crispr Therapeutics AG’s shares valued at 352M.
---
Crispr Therapeutics AG Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$67.94 (65.63% Upside)
$67.94 (65.63% Upside)
Blogger Sentiment
Bullish
CRSP Sentiment 94%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 113.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.43%
12-Months-Change
Fundamentals
Return on Equity
-13.07%
Trailing 12-Months
Asset Growth
8.11%
Trailing 12-Months
Company Description
Crispr Therapeutics AG
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
---
CRSP Stock 12 Month Forecast
Average Price Target
$67.94
▲(65.63% Upside)
Technical Analysis
Best Analysts Covering CRSP
1 Year
1 Year Success Rate
17/40 ratings generated profit
1 Year Average Return
+17.85%
reiterated a buy rating 26 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 42.50% of your transactions generating a profit, with an average return of +17.85% per trade.
---